LumiThera is committed to creating brighter horizons for patients by developing treatment solutions utilizing Photobiomodulation to improve visual function, to stop or slow the progression of debilitating eye diseases, and to prevent vision loss and blindness.
LumiThera’s flagship product, the Valeda® Light Delivery System, is the first approved treatment for Dry Age-Related Macular Degeneration using Photobiomodulation. Valeda improves visual acuity, improves contrast sensitivity, reduces central drusen volume, and is designed for ease-of-use in the clinician’s office.
Valeda is CE Marked in Europe and is in clinical trials and not approved for use in the United States. Visit www.lumithera.com to learn more.